Market Updates: Key Upgrades and Downgrades

Wall Street has been buzzing about various research requests that are influencing market movements. Here’s a summary of today’s notable findings that investors should take note of.

Top 5 Upgrades:

• JP Morgan is optimistic about NetEase (NTES), moving its rating from Neutral to Overweight and raising the price target from $138 to $190. The firm is excited about the upcoming game releases scheduled for 2026.

• Morgan Stanley has revised its rating on Sienna (CIEN), shifting from Underweight to Equal Weight, with a price target increase from $100 to $140. They believe concerns about margins were overstated, especially as demand trends are improving.

• HSBC upgraded Synchrony (SYF), adjusting its rating to “Buy” from Hold and increasing the price target from $73 to $81. The rationale includes Synchrony’s solid credit performance and promising growth prospects.

• Macquarie has upgraded Baidu (BIDU), changing the price target range from $91 to $176, with a rating change from Neutral to Outperform. They noted Baidu’s diversification in revenue streams, particularly in cloud services and AI technologies.

• Baird has changed its outlook on Littelfuse (LFUS), raising the price target from $290 to $310, now rating it as Outperform. The firm highlighted that Littelfuse’s engagement in artificial intelligence is already yielding positive early results.

Top 5 Downgrades:

• Jefferies downgraded Align Technology (ALGN), lowering the price target from $215 to $140 and shifting the rating from Buy to Hold. Recent dental surveys in the U.S. reflected mixed and negative sentiment about clear aligners, contributing to Align’s stock decline.

• RBC Capital has downgraded Mosaic (MOS) from Outperform to Sector Perform and reduced the price target from $40 to $30. They expressed disappointment over another unexpected phosphate production cut, which they believe will hurt Mosaic’s stock considerably.

• JP Morgan has downgraded Doximity (DOCS) from Neutral to Underweight, keeping the price target steady at $62. They view the stock’s premium valuation as excessive and noted that uncertain trends in pharmaceutical digital advertising are obscuring Doximity’s growth potential.

• JP Morgan also downgraded Pliant Therapeutics (PLRX) from Neutral to Underweight without a price target. The firm commented on the stalled investment discussions following the discontinuation of its bexotegrast program for idiopathic pulmonary fibrosis, suggesting the company is now in a waiting phase.

• Morgan Stanley adjusted its outlook on Keysight Technology (KEYS), changing the rating from Overweight to Equal Weight while keeping the price target unchanged at $180. They noted that the stock has already reached its target price, lacking additional catalysts for a re-evaluation.